Research Topics
| Pablo TebasSummaryAffiliation: University of Pennsylvania Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
Insulin resistance and diabetes mellitus associated with antiretroviral use in HIV-infected patients: pathogenesis, prevention, and treatment optionsPablo Tebas
AIDS Clinical Trials Unit, University of Pennsylvania, Philadelphia, PA 19104 4283, USA
J Acquir Immune Defic Syndr 49:S86-92. 2008..Optimization of antiretroviral treatment regimens for HIV-infected patients with or at increased risk for development of abnormalities in glucose metabolism is discussed...
HIV and cardiometabolic abnormalities: new perspectives and treatment updatePablo Tebas
University of Pennsylvania, AIDS Clinical Trials Unit, Philadelphia, PA 19104-4283, USA
J Acquir Immune Defic Syndr 49:S77-8. 2008
Metabolic and immune activation effects of treatment interruption in chronic HIV-1 infection: implications for cardiovascular riskPablo Tebas
University of Pennsylvania, Philadelphia, Pennsylvania, United States of America
PLoS ONE 3:e2021. 2008..Our goal was to evaluate fasting metabolic changes associated with interruption of antiretroviral therapy and relate them to changes of immune activation markers and cardiovascular risk...- Switching to a protease inhibitor-containing, nucleoside-sparing regimen (lopinavir/ritonavir plus efavirenz) increases limb fat but raises serum lipid levels: results of a prospective randomized trial (AIDS clinical trial group 5125s)Pablo Tebas
Division of Infectious Diseases, University of Pennsylvania, Philadelphia, PA 19104, USA
J Acquir Immune Defic Syndr 45:193-200. 2007..Subcutaneous limb fat loss continues to be one the most troubling side effects of long-term antiretroviral regimens. Nucleoside analogues and protease inhibitors (PIs) have been linked to the development of this complication... - Peripheral and visceral fat changes following a treatment switch to a non-thymidine analogue or a nucleoside-sparing regimen in HIV-infected subjects with peripheral lipoatrophy: results of ACTG A5110P Tebas
University of Pennsylvania, Philadelphia, USA
J Antimicrob Chemother 63:998-1005. 2009..Switching a thymidine analogue to a non-thymidine analogue or changing to a nucleoside-sparing regimen has been shown to partially reverse peripheral lipoatrophy. The current study evaluated both approaches... - Interventions for body habitus changes associated with HIV infection and its treatmentPablo Tebas
University of Pennsylvania, AIDS Clinical Research Unit, 3451 Walnut Street, Philadelphia, PA 19104, USA
Curr HIV/AIDS Rep 4:86-92. 2007..This review discusses the current management of these complications of HIV and its treatment. For the purpose of clarity in this review, we have divided the interventions according to the predominant phenotype of the individual... - Poor immunogenicity of the H1N1 2009 vaccine in well controlled HIV-infected individualsPablo Tebas
University of Pennsylvania School of Medicine, Philadelphia, USA
AIDS 24:2187-92. 2010..To evaluate the safety and immunogenicity of the H1N1 2009 vaccine in HIV-positive individuals... - A randomized, placebo controlled, double masked phase IB study evaluating the safety and antiviral activity of aprepitant, a neurokinin-1 receptor antagonist in HIV-1 infected adultsPablo Tebas
Division of Infectious Diseases, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America
PLoS ONE 6:e24180. 2011..Neurokinin-1 receptor (NK1R) antagonists have anti-HIV activity in monocyte-derived macrophages, decrease CCR5 expression and improve natural killer cell function ex vivo. Aprepitant is a NK1R antagonist approved by FDA as an antiemetic... - Enfuvirtide does not require dose adjustment in patients with chronic kidney failure: results of a pharmacokinetic study of enfuvirtide in HIV-1-infected patients with impaired kidney functionPablo Tebas
University of Pennsylvania, Hospital of the University of Pennsylvania, Philadelphia, PA 19104, USA
J Acquir Immune Defic Syndr 47:342-5. 2008..The aim of this study was to examine the influence of kidney disease and hemodialysis on the pharmacokinetics ofenfuvirtide... - Long-term body fat outcomes in antiretroviral-naive participants randomized to nelfinavir or efavirenz or both plus dual nucleosides. Dual X-ray absorptiometry results from A5005s, a substudy of Adult Clinical Trials Group 384Michael P Dube
Division of Infectious Diseases, Indiana University, Indianapolis, USA
J Acquir Immune Defic Syndr 45:508-14. 2007..Long-term regional body fat outcomes have not been well described in randomized antiretroviral drug trials... - Effects of potent antiretroviral therapy on free testosterone levels and fat-free mass in men in a prospective, randomized trial: A5005s, a substudy of AIDS Clinical Trials Group Study 384Michael P Dube
Division of Infectious Diseases, Indiana University, Indianapolis, USA
Clin Infect Dis 45:120-6. 2007..The effects of initiation of different antiretroviral regimens on testosterone levels and changes in fat-free mass have not been reported... - Management of chronic hepatitis B in an HIV-positive patient with 3TC-resistant hepatitis B virusMaria Ristig
Division of Infectious Diseases, Hepatology Program, Washington University School of Medicine, St. Louis, Missouri, USA
AIDS Patient Care STDS 17:439-42. 2003..The patient was subsequently removed from the liver transplant program and has not suffered from any further hepatic complications... - Prevalence, risk factors, and outcomes for occult hepatitis B virus infection among HIV-infected patientsVincent Lo Re
Division of Infectious Diseases, Department of Medicine, University of Pennsylvania School of Medicine, 423 Guardian Drive, Philadelphia, PA 19104, USA
J Acquir Immune Defic Syndr 44:315-20. 2007..The prevalence of occult HBV in HIV-infected patients remains controversial, and the risk factors and clinical significance are unknown... - Improved immunogenicity with high-dose seasonal influenza vaccine in HIV-infected persons: a single-center, parallel, randomized trialNoah McKittrick
University of Pennsylvania, Philadelphia, PA 19104, USA
Ann Intern Med 158:19-26. 2013..HIV-infected persons have less robust antibody responses to influenza vaccines... - Abacavir/lamivudine versus tenofovir DF/emtricitabine as part of combination regimens for initial treatment of HIV: final resultsPaul E Sax
Division of Infectious Diseases, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
J Infect Dis 204:1191-201. 2011..Due to higher virologic failure with ABC/3TC in the high HIV RNA stratum, blinded treatment was stopped in this group, but study follow-up continued for all patients... - Niacin in HIV-infected individuals with hyperlipidemia receiving potent antiretroviral therapyMarisa T Gerber
Division of Infectious Diseases, Department of Internal Medicine, Washington University School of Medicine, Saint Louis, MO, USA
Clin Infect Dis 39:419-25. 2004.... - Hemochromatosis gene polymorphisms, mitochondrial haplogroups, and peripheral lipoatrophy during antiretroviral therapyTodd Hulgan
Division of Infectious Diseases, Vanderbilt University School of Medicine, Nashville, Tennessee 37203, USA
J Infect Dis 197:858-66. 2008..Mitochondrial haplogroups and hemochromatosis gene (HFE) polymorphisms have been associated with ART-induced neuropathy. We assessed relationships between these variants and lipoatrophy... - Antiviral effects of autologous CD4 T cells genetically modified with a conditionally replicating lentiviral vector expressing long antisense to HIVPablo Tebas
Department of Medicine and Center for AIDS Research, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA
Blood 121:1524-33. 2013..We conclude that gene-modified T cells have the potential to decrease the fitness of HIV-1 and conditionally replicative lentiviral vectors have a promising safety profile in T cells... - Alendronate, vitamin D, and calcium for the treatment of osteopenia/osteoporosis associated with HIV infectionKristin Mondy
Washington University School of Medicine, Division of Infectious Diseases, St. Louis, MO, USA
J Acquir Immune Defic Syndr 38:426-31. 2005..There were no serious adverse events. CONCLUSIONS: Alendronate, vitamin D, and calcium are safe and potentially useful in the treatment of osteopenia/osteoporosis associated with HIV infection... - Glucose metabolism, lipid, and body fat changes in antiretroviral-naive subjects randomized to nelfinavir or efavirenz plus dual nucleosidesMichael P Dube
Division of Infectious Diseases, Indiana University, Indianapolis, Indiana, USA
AIDS 19:1807-18. 2005..To determine if particular components of antiretroviral drug regimens are associated with greater insulin resistance, dyslipidemia, and peripheral lipoatrophy... - Analysis of lentiviral vector integration in HIV+ study subjects receiving autologous infusions of gene modified CD4+ T cellsGary P Wang
Department of Microbiology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104 6076, USA
Mol Ther 17:844-50. 2009.... - Vitamin D deficiency is associated with type 2 diabetes mellitus in HIV infectionZsofia Szep
Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania School of Medicine, USA
AIDS 25:525-9. 2011..Low vitamin D levels increase the risk of type 2 diabetes mellitus, and vitamin D supplementation has been shown to decrease the risk of type 2 diabetes mellitus in patients without HIV infection... - A tale of 2 epidemics: the intersection between obesity and HIV infection in PhiladelphiaValerianna Amorosa
Division of Infectious Diseases, University of Pennsylvania, Philadelphia, PA 19104-6073, USA
J Acquir Immune Defic Syndr 39:557-61. 2005..Women, particularly those of African American race, are at high risk. Obesity might add to metabolic abnormalities associated with HIV or its treatment and contribute to morbidity, as patients with HIV live longer... - Risk of hip fracture associated with hepatitis C virus infection and hepatitis C/human immunodeficiency virus coinfectionVincent Lo Re
Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
Hepatology 56:1688-98. 2012..HCV-monoinfected patients had an increased risk of hip fracture, compared to uninfected individuals... - Neurokinin-1 receptor antagonist (aprepitant) inhibits drug-resistant HIV-1 infection of macrophages in vitroXu Wang
Division of Allergy and Immunology, Children s Hospital of Philadelphia, Department of Pediatrics, University of Pennsylvania School of Medicine, Philadelphia, PA, USA
J Neuroimmune Pharmacol 2:42-8. 2007..Aprepitant is in clinical use for the prevention of nausea and vomiting associated with cancer chemotherapy or following surgical procedures... - Massively parallel pyrosequencing in HIV researchFrederic D Bushman
Department of Microbiology, University of Pennsylvania School of Medicine, 3610 Hamilton Walk, Philadelphia, PA 19104-6076, USA
AIDS 22:1411-5. 2008 - Bone disease and HIV infectionValerianna Amorosa
Division of Infectious Diseases, University of Pennsylvania School of Medicine, Philadelphia, PA, USA
Clin Infect Dis 42:108-14. 2006.... - Viral hepatitis is associated with reduced bone mineral density in HIV-infected women but not menVincent Lo Re
Division of Infectious Diseases, Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104 6021, USA
AIDS 23:2191-8. 2009..Few studies have examined the impact of viral hepatitis on bone mineral density (BMD), and none have done so among HIV-infected patients. Our objective was to determine whether viral hepatitis was associated with low BMD in HIV... - Emerging bone problems in patients infected with human immunodeficiency virusKristin Mondy
Division of Infectious Diseases, AIDS Clinical Trials Unit, Washington University School of Medicine, St. Louis, Missouri 63110, USA
Clin Infect Dis 36:S101-5. 2003..Hormone replacement and antiresorptive therapies might be also indicated... - Impact of transitioning from HIV clinical trials to routine medical care on clinical outcomes and patient perceptionsBaligh R Yehia
Department of Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, USA
AIDS Care 24:769-77. 2012..Patients without a healthy fear of transitioning from ART-RCTs to routine care may be at increased risk of viral failure. Focus should be given to assisting patients during this transition... - DNA bar coding and pyrosequencing to identify rare HIV drug resistance mutationsChristian Hoffmann
Department of Microbiology, University of Pennsylvania School of Medicine, 3610 Hamilton Walk, Philadelphia, PA 19104 6076, USA
Nucleic Acids Res 35:e91. 2007.... - Nonnucleoside reverse transcriptase inhibitor resistance among antiretroviral-naive HIV-positive pregnant womenSalome N Juethner
Division of Infectious Diseases, Washington University School of Medicine, St. Louis, Missouri 63108, USA
J Acquir Immune Defic Syndr 32:153-6. 2003.... - Pegylated Interferon alfa-2a monotherapy results in suppression of HIV type 1 replication and decreased cell-associated HIV DNA integrationLivio Azzoni
1HIV 1 Immunopathogenesis Laboratory, The Wistar Institute, Philadelphia, PA, USA
J Infect Dis 207:213-22. 2013..Antiretroviral therapy (ART)-mediated immune reconstitution fails to restore the capacity of the immune system to spontaneously control human immunodeficiency virus (HIV) replication... - Management of potential neurocysticercosis in patients with HIV infectionSashank Prasad
Department of Neurology, University of Pennsylvania, Philadelphia, PA, USA
Clin Infect Dis 42:e30-4. 2006..We report 3 cases and suggest including the CD4+ T lymphocyte count as an important factor in the proper diagnosis and treatment of patients with human immunodeficiency virus and potential neurocysticercosis... - Distinct mechanisms of T cell reconstitution can be identified by estimating thymic volume in adult HIV-1 diseaseRobert C Kalayjian
Division of Infectious Diseases, MetroHealth Medical Center and Case Western Reserve University, Cleveland, Ohio 44109 1998, USA
J Infect Dis 192:1577-87. 2005..We have attempted to identify factors associated with T cell reconstitution in response to highly active antiretroviral therapy... - Human immunodeficiency virus type 1 Nef induces programmed death 1 expression through a p38 mitogen-activated protein kinase-dependent mechanismKaruppiah Muthumani
Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
J Virol 82:11536-44. 2008..These data demonstrate an important signaling event of Nef in HIV-1 pathogenesis... - The use of HAART is associated with decreased risk of death during initial treatment of cryptococcal meningitis in adults in BotswanaGregory P Bisson
Department of Medicine, University of Pennsylvania School of Medicine, 423 Guardian Drive, Philadelphia, PA 19104, USA
J Acquir Immune Defic Syndr 49:227-9. 2008..The objective of this study was to evaluate outcomes among adults with a first episode of cryptococcal meningitis (CM), comparing those on highly active antiretroviral therapy (HAART) with those not on HAART... - Longitudinal evolution of bone mineral density and bone markers in human immunodeficiency virus-infected individualsKristin Mondy
Division of Infectious Diseases, Department of Internal Medicine, Washington University School of Medicine, St. Louis, MO 63108, USA
Clin Infect Dis 36:482-90. 2003..Traditional risk factors and advanced HIV infection play a more significant pathogenic role in the development of osteopenia and osteoporosis associated with HIV infection than do treatment-associated factors... - Is it time to rethink the expanded-access programs for HIV infection?Valerianna Amorosa
University of Pennsylvania, Philadelphia, PA 19104, USA
J Infect Dis 196:974-7. 2007.... - Plasmid vaccination of stable HIV-positive subjects on antiviral treatment results in enhanced CD8 T-cell immunity and increased control of viral "blips"Rob Roy MacGregor
Department of Medicine, University of Pennsylvania School of Medicine, 502 Johnson Pavilion, 36th and Hamilton Walk, Philadelphia, PA 19104-6073, USA
Vaccine 23:2066-73. 2005..04). The decrease in the frequency of transient viremia and failure suggests that DNA immunization with CD8-generating vaccines in HAART-controlled HIV-positive subjects may have therapeutic potential... - Early versus delayed antiretroviral therapy and cerebrospinal fluid fungal clearance in adults with HIV and cryptococcal meningitisGregory P Bisson
Department of Medicine, Division of Infectious Diseases, Perelman School of Medicine, University of Pennsylvania, and The Children s Hospital of Philadelphia, Philadelphia, PA 19104 6021, USA
Clin Infect Dis 56:1165-73. 2013..This study tested the hypothesis that initiation of ART during initial treatment of HIV/CM would improve CSF clearance of C. neoformans... - Tenofovir disoproxil fumarate therapy for chronic hepatitis B in human immunodeficiency virus/hepatitis B virus-coinfected individuals for whom interferon-alpha and lamivudine therapy have failedMaria B Ristig
Division of Infectious Diseases, Washington University School of Medicine, St. Louis, Missouri 63108, USA
J Infect Dis 186:1844-7. 2002..There was a transient increase of transaminases after the initiation of treatment. No patient developed HBe antibodies. TDF is a very promising drug for the treatment of chronic hepatitis B in HIV-infected individuals... - Osteoporotic fracture risk associated with cumulative exposure to tenofovir and other antiretroviral agentsRoger Bedimo
Department of Medicine, VA North Texas Healthcare System, Dallas, Texas, USA
AIDS 26:825-31. 2012..Whereas tenofovir (TDF) exposure has been associated with decreased bone density, it remains unclear whether it is associated with increased risk of osteoporotic fractures... - HIV-mediated phosphatidylinositol 3-kinase/serine-threonine kinase activation in APCs leads to programmed death-1 ligand upregulation and suppression of HIV-specific CD8 T cellsKaruppiah Muthumani
Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
J Immunol 187:2932-43. 2011..These data identify a novel mechanism by which HIV exploits the immunosuppressive PD-1 pathway and suggest a new role for virus-infected cells in the local corruption of immune responses required for viral suppression... - Subgroup analyses of maraviroc in previously treated R5 HIV-1 infectionGerd Fatkenheuer
Universitätsklinik Köln, Cologne, Germany
N Engl J Med 359:1442-55. 2008.... - Maraviroc for previously treated patients with R5 HIV-1 infectionRoy M Gulick
Weill Cornell Medical College, New York, NY 10065, USA
N Engl J Med 359:1429-41. 2008..CC chemokine receptor 5 antagonists are a new class of antiretroviral agents... - Genetic analysis implicates resistin in HIV lipodystrophyKoustubh Ranade
Bristol Myers Squibb R and D, Princeton, New Jersey 08543 5400, USA
AIDS 22:1561-8. 2008..To investigate the role of genetic variation in influencing the risk of metabolic complications associated with highly active antiretroviral therapy (HAART)... - On antiretroviral guidelines and evidence based medicinePablo Tebas
Enferm Infecc Microbiol Clin 20:241-3. 2002 - Early intensification with abacavir in subjects at high risk for incomplete viral suppressionJohn A Bartlett
Antivir Ther 8:361-3. 2003 - Evaluation of the virological and metabolic effects of switching protease inhibitor combination antiretroviral therapy to nevirapine-based therapy for the treatment of HIV infectionPablo Tebas
Washington University School of Medicine, St. Louis, Missouri 63110, USA
AIDS Res Hum Retroviruses 20:589-94. 2004..Our study supports a pathogenic role for PIs in the development of hypertriglyceridemia and insulin resistance, but a more limited role in the fat redistribution syndrome... - Fat redistribution and bone abnormalities in HIV-infected patientsPablo Tebas
Washington University, 4511 Forest Park, Suite 304, Saint Louis, MO 63108, USA
J Int Assoc Physicians AIDS Care (Chic Ill) 2:59-65. 2003 - Associations among race/ethnicity, ApoC-III genotypes, and lipids in HIV-1-infected individuals on antiretroviral therapyAndrea S Foulkes
School of Public Health and Health Sciences, University of Massachusetts, Amherst, Massachusetts, United States of America
PLoS Med 3:e52. 2006..However, the association of race/ethnicity, or candidate gene effects across race/ethnicity, with plasma lipid levels in HIV-1-infected individuals, has not been reported... - Real-time nucleic acid sequence-based amplification assay to quantify changes in mitochondrial DNA concentrations in cell cultures and blood cells from HIV-infected patients receiving antiviral therapyEveline C Timmermans
Primagen, Amsterdam, The Netherlands
Clin Chem 52:979-87. 2006..008). CONCLUSION: After drug exposure, the mtDNA assay can detect changes in mtDNA concentrations in cell lines and PBMCs, when properly controlled for platelet effects, earlier than traditional assays... - Effect of prolonged discontinuation of successful antiretroviral therapy on CD4+ T cell decline in human immunodeficiency virus-infected patients: implications for intermittent therapeutic strategiesPablo Tebas
Washington University School of Medicine, St Louis, Missouri 63108, USA
J Infect Dis 186:851-4. 2002..In a multiple regression analysis model, the increase of CD4(+) T cells while receiving therapy and age were independently associated with the rate of CD4(+) T cell loss... - A pilot study evaluating time to CD4 T-cell count <350 cells/mm(3) after treatment interruption following antiretroviral therapy +/- interleukin 2: results of ACTG A5102Keith Henry
HIV Program, Hennepin County Medical Center and the University of Minnesota, Minneapolis, MN 55415, USA
J Acquir Immune Defic Syndr 42:140-8. 2006..By boosting CD4 T-cell counts, interleukin 2 (IL-2) could safely prolong the duration of treatment interruption (TI) in a CD4-driven strategy... - Granulocyte-macrophage colony-stimulating factor induces modest increases in plasma human immunodeficiency virus (HIV) type 1 RNA levels and CD4+ lymphocyte counts in patients with uncontrolled HIV infectionJeffrey M Jacobson
Department of Medicine, Beth Israel Medical Center and Albert Einstein College of Medicine, New York, New York 10003, USA
J Infect Dis 188:1804-14. 2003..Studies have reported that plasma human immunodeficiency virus type 1 (HIV-1) RNA levels and CD4+ lymphocyte counts in HIV-infected patients improved after treatment with granulocyte-macrophage colony-stimulating factor (GM-CSF)... - Cyclosporin A provides no sustained immunologic benefit to persons with chronic HIV-1 infection starting suppressive antiretroviral therapy: results of a randomized, controlled trial of the AIDS Clinical Trials Group A5138Michael M Lederman
Case Western Reserve University, University Hospitals of Cleveland, Cleveland, OH 44106, USA
J Infect Dis 194:1677-85. 2006..Although the determinants of immune deficiency and immune restoration in chronic human immunodeficiency virus (HIV)-1 infection are not well understood, immune activation has been proposed as being central to the pathogenesis of HIV... - Cardiovascular risks of antiretroviral therapiesKristin Mondy
Washington University School of Medicine, Saint Louis, Missouri 63110, USA
Annu Rev Med 58:141-55. 2007..Optimal selection of metabolically neutral antiretroviral therapies, together with aggressive management of other modifiable coronary risk factors, may improve cardiovascular disease risk in the long term... - Randomized open-label trial of two simplified, class-sparing regimens following a first suppressive three or four-drug regimenMargaret A Fischl
AIDS Clinical Research Unit R 60A, Department of Medicine, University of Miami School of Medicine, 1800 NW 10th Avenue, Miami, FL 33136, USA
AIDS 21:325-33. 2007..Complex antiretroviral regimens can be associated with increased toxicity and poor adherence. Our aim was to compare the efficacy and safety of switching to two simplified, class-sparing antiretroviral regimens... - Progression of carotid artery intima-media thickening in HIV-infected and uninfected adultsJudith S Currier
Center for Clinical AIDS Research and Education, David Geffen School of Medicine at the University of California, Los Angeles, CA, USA
AIDS 21:1137-45. 2007..To compare the rate of change in intima-media thickness (IMT) of the carotid artery among uninfected subjects and HIV-infected subjects receiving or not receiving protease inhibitor (PI) regimens over a 144 week period... - The virologic, immunologic, and clinical effects of interleukin 2 with potent antiretroviral therapy in patients with moderately advanced human immunodeficiency virus infection: a randomized controlled clinical trial--AIDS Clinical Trials Group 328Ronald Mitsuyasu
Department of Internal Medicine, University of California Los Angeles, USA
Arch Intern Med 167:597-605. 2007..Interleukin 2 (IL-2) administration increases CD4 counts in persons with higher counts. This study investigated persons with moderately advanced human immunodeficiency virus infection receiving highly active antiretroviral therapy (HAART)... - Once-daily antiretroviral therapies for HIV infection: Consensus Statement of an Advisory Committee of the International Association of Physicians in AIDS CareCalvin Cohen
CRI New England, 23 Miner Street, Boston, Massachusetts 02215-3318, USA
J Int Assoc Physicians AIDS Care (Chic Ill) 1:141-5. 2002..The opinions expressed in this Consensus Statement represent only those of the Advisory Committee... - Visceral adiposity, C-peptide levels, and low lipase activities predict HIV-dyslipidemiaKevin E Yarasheski
Division of Endocrinology, Metabolism and Lipid Research, Washington University Medical School, 660 South Euclid Avenue, Box 8127, St Louis, MO 63110, USA
Am J Physiol Endocrinol Metab 285:E899-905. 2003..g., central adiposity and hyperinsulinemia) and mediated only partially by factors that influence triglyceride clearance (e.g., lipase activity)... - HIV-protease inhibitors impair vitamin D bioactivation to 1,25-dihydroxyvitamin DMario Cozzolino
Department of Internal Medicine, Washington University School of Medicine, St Louis, Missouri, USA
AIDS 17:513-20. 2003..If PIs elicit a similar potency in inhibiting these critical steps for 1,25(OH) D homeostasis, defective 1,25(OH) D production could contribute to the bone demineralization in HIV patients... - A phase II randomized study of the virologic and immunologic effect of zidovudine + stavudine versus stavudine alone and zidovudine + lamivudine in patients with >300 CD4 cells who were antiretroviral naive (ACTG 298)Richard B Pollard
University of California Davis Medical Center, Patient Support Services Building, 4150 V Street, Suite G500, Sacramento, CA 95817, USA
AIDS Res Hum Retroviruses 18:699-704. 2002..Based on this study and other data, combining d4T and ZDV is not recommended... - Cure of acute hepatitis C in HIV co-infection?Maria B Ristig
J Clin Gastroenterol 38:303. 2004 - [Delayed diagnosis of HIV infection in the Spanish VACH cohort [1997-2002]]Ramón Teira Cobo
Servicio de Enfermedades Infecciosas, Hospital de Basurto, Bilbao, Espana
Gac Sanit 21:66-9. 2007..To study the prevalence of delayed diagnosis of HIV infection and associated factors... - The HIV protease inhibitor ritonavir blocks osteoclastogenesis and function by impairing RANKL-induced signalingMichael W-H Wang
Department of Pathology and Immunology, Washington University School of Medicine, Campus Box 8118, 660 South Euclid Avenue, St. Louis, Missouri 63110, USA
J Clin Invest 114:206-13. 2004..Thus, ritonavir may represent a bone-sparing PI capable of preventing development of osteopenia in patients currently on HAART... - Effects of the G190A substitution of HIV reverse transcriptase on phenotypic susceptibility of patient isolates to delavirdineErik J Uhlmann
Department of Pathology, Box 8118, Washington University School of Medicine, 660 South Euclid Avenue, St. Louis, MO 63110, USA
J Clin Virol 31:198-203. 2004..The in vivo significance of the increased phenotypic susceptibility to delavirdine is not known but could be evaluated in a clinical trial... - Treating morphologic and metabolic complications in HIV-infected patients on antiretroviral therapy. A consensus statement of an advisory committee of the International Association of Physicians in AIDS CareCarl J Fichtenbaum
IAPAC Mon 11:38-46. 2005..Scientific and clinical research, and other data in published literature and abstracts from scientific conferences were considered by strength of evidence. This document represents the consensus agreement of the Advisory Committee... - Mixed patterns of changes in central and peripheral fat following initiation of antiretroviral therapy in a randomized trialKathleen Mulligan
Department of Medicine, Division of Endocrinology, San Francisco General Hospital, University of California at San Francisco, San Francisco, CA, USA
J Acquir Immune Defic Syndr 41:590-7. 2006..Increased waist/hip ratio was predominantly associated with increased waist circumference. There was no evidence that central fat accumulation and peripheral fat loss are linked in most subjects... - Explaining, predicting, and treating HIV-associated CD4 cell loss: after 25 years still a puzzleW Keith Henry
JAMA 296:1523-5. 2006 - Alendronate with calcium and vitamin D supplementation is safe and effective for the treatment of decreased bone mineral density in HIVGrace A McComsey
Rainbow Babies and Children s Hospital and Case Western Reserve University, Cleveland, Ohio, USA
AIDS 21:2473-82. 2007..Bisphosphonates are currently the mainstay of treatment for postmenopausal and male osteoporosis in HIV-uninfected individuals; however, their efficacy and safety in HIV-infected patients remains unclear...
Research Grants
- Mitochondria And Metabolic Complications Of HIVPablo Tebas; Fiscal Year: 2006..In order to do this we will use a NASBA based assay to measure the mitochondrial DNA and RNA content in PBMCs, and use 2000 specimens collected longitudinally in 3 large ACTG studies. ..
- AIDS CLINICAL TRIALS UNITPablo Tebas; Fiscal Year: 2007..The investigators have credentials in basic and patient-oriented clinical research. ..